Chiesi has a passionate commitment to innovation in terms of both active ingredients and new formulations. Seventeen patent applications were filed in 2014 resulting in an exceptionally promising pipeline of potential new medicines.
Chiesi invests 15–20% of the total turnover of the Chiesi group every year into research and development.
Our Research and Development team represents a fundamental asset in our business. It comprises multi-functional business areas (focussing on pipeline projects), which include:
Moreover, research and development functions also support products already on the market through pharmacovigilance and regulatory activities.
Our traditional research and development focus is now complemented by new research areas in rare diseases, biotechnology, gene therapy and transplantation.